Clinical Trials
Monday, October 22nd, 2012
John Wiley & Sons, Inc.: OCT 9, 2012 WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia, and AF is associated with relatively higher all-cause mortality in both men and women. • However, there are limited treatment options for AF. • Statins are hypothesized to have a benefit against […]
Clinical Trials
Monday, October 22nd, 2012
Biostatistics: September 21, 2012 Individual patient-data meta-analysis of randomized controlled trials is the gold standard for investigating how patient factors modify the effectiveness of treatment. Because participant data from primary studies might not be available, reliable alternatives using published data are needed. In this paper, I show that the maximum likelihood estimates of a participant-level linear […]
Clinical Trials
Monday, October 22nd, 2012
Longer Atrial Fibrillation–Free Survival Time but Similar Survival Time Free of Any Atrial Arrhythmia American Heart Association, Inc.: September 12, 2012 Electric isolation of the pulmonary veins and posterior left atrium with a single ring of radiofrequency lesions (single-ring isolation [SRI]) may result in fewer atrial fibrillation (AF) recurrences than wide antral pulmonary vein isolation (wide […]
Clinical Trials
Thursday, October 11th, 2012
Nih.gov: 10/10/12 A workshop sponsored by NIH’s National Institute of Neurological Disorders and Stroke (NINDS) has produced a set of consensus recommendations to improve the design and reporting of animal studies. By making animal studies easier to replicate and interpret, the workshop recommendations are expected to help funnel promising therapies to patients. Biomedical research involving […]
Clinical Trials
Thursday, October 11th, 2012
Thelancet.com: 10/8/12 Background Neuroprotection with NA-1 (Tat-NR2B9c), an inhibitor of postsynaptic density-95 protein, has been shown in a primate model of stroke. We assessed whether NA-1 could reduce ischaemic brain damage in human beings. Methods For this double-blind, randomised, controlled study, we enrolled patients aged 18 years or older who had a ruptured or unruptured […]
Clinical Trials
Thursday, October 11th, 2012
Thelancet.com: 10/6/12 Background The Solitaire Flow Restoration Device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia. We compared the efficacy and safety of Solitaire with the standard, predicate mechanical thrombectomy device, the Merci Retrieval System. Methods In this randomised, parallel-group, non-inferiority trial, we enrolled patients from 18 […]
Clinical Trials
Thursday, October 11th, 2012
Thelancet.com: 10/6/12 Background Present mechanical devices are unable to achieve recanalisation in up to 20—40% of large vessel occlusion strokes. We compared efficacy and safety of the Trevo Retriever, a new stent-like device, with its US Food and Drug Administration-cleared predecessor, the Merci Retriever. Methods In this open-label randomised controlled trial, we recruited patients at […]
Clinical Trials
Thursday, October 11th, 2012
Ns.umich.edu: 10/3/12 ANN ARBOR, Mich.—Large amounts of missing data in clinical trials can undermine the scientific credibility of the studies, according to a special report by an expert panel commissioned by the National Research Council. The panel, chaired by Roderick Little, the Richard D. Remington Collegiate Professor of Biostatistics at the University of Michigan School […]
Clinical Trials
Friday, October 5th, 2012
Neurology.org: October 3, 2012 This study aims to evaluate protective effects of brief repetitive bilateral arm ischemic preconditioning (BAIPC) on stroke recurrence in patients with symptomatic atherosclerotic intracranial arterial stenosis (IAS). Methods: A total of 68 consecutive cases with symptomatic IAS, diagnosed by imaging, were enrolled in this prospective and randomized study. All patients received standard medical […]
Clinical Trials
Friday, October 5th, 2012
Thelancet.com: October 22, 012 The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in lower mortality. We assessed in this trial’s participants how results differed according to patients’ CHADS2, CHA2DS2VASc, and […]
